HDAC inhibitor SAHA enhances antitumor immunity via the HDAC1/JAK1/FGL1 axis in lung adenocarcinoma
Journal for ImmunoTherapy of Cancer · 2024-10 · 12 (10) · e010077
DOI: 10.1136/jitc-2024-010077 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 09.10.2024. Verfasst von Tingting Xu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: Histone Deacetylase Inhibitors, Histone Deacetylase 1, Lung Neoplasms, Adenocarcinoma of Lung. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Beijing Xisike Clinical Oncology Research Foundation, Jiangsu Province Capability Improvement Project, National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Histone deacetylase (HDAC), a kind of protease that regulates gene expression by modifying protein acetylation levels, is usually aberrantly activated in tumors. The approved pan-HDAC inhibitors (HDACi) have exhibited clinical benefits for hematopoietic malignancies. Recently, HDACis have emerged as enhancers of antitumor immunity. However, the effect of HDACs on the tumor immune microenvironment of lung adenocarcinoma (LUAD) and the underlying mechanism is largely unknown.
Methods
C57BL/6J and BALB/c nude mice with subcutaneous tumors were used for in vivo therapeutic effects and mechanistic investigations. Flow cytometry was used to measure the toxicity and exhaustion of human CD8+T cells after co-culturing with tumor cells and to determine the immunophenotype of tumor-infiltrating CD8+T cells. A series of experimental techniques, including RNA sequencing, quantitative PCR, western blot, ELISA, mass spectrometry, co-immunoprecipitation, chromatin immunoprecipitation and immunohistochemistry, were used to explore the underlying molecular mechanism.
Results
The pan-HDACi vorinostat (SAHA) promoted CD8+T cell infiltration and effector function in LUAD through suppressing FGL1, a newly identified major ligand of LAG-3. Mechanistically, SAHA inhibited the activity of HDAC1, an essential deacetylase of JAK1. This increased the acetylation level of JAK1 at lysine 1109, thus promoting its proteasomal degradation and subsequently reducing STAT3-driven FGL1 transcription. The combination regimen of SAHA and anti-LAG-3 therapy was further explored in an immunocompetent LUAD mouse model. Compared with those receiving control or single agent treatments, mice receiving combination therapy exhibited a lower tumor burden and superior CD8+T-cell-killing activity.
Conclusions
Our results revealed a novel mechanism by which the HDACi SAHA potentiates CD8+T-cell-mediated antitumor activity through the HDAC1/JAK1/FGL1 axis, providing a rationale for the combined use of HDACis and immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
- Department of Oncology, Gusu School, Suzhou Municipal Hospital, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, China.
- Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China yongqian_shu@163.com mapei@njmu.edu.cn.
- Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China.
ORCID-Profile: Tingting Xu
Förderung
- Beijing Xisike Clinical Oncology Research Foundation
- Jiangsu Province Capability Improvement Project
- National Natural Science Foundation of China
- High-level Talent Cultivation Program
Zitieren
APA
Xu, T., Fang, Y., Gu, Y., Xu, D., Hu, T., Yu, T., Xu, Y. Y., Shen, H. Y., Ma, P., & Shu, Y. (2024). HDAC inhibitor SAHA enhances antitumor immunity via the HDAC1/JAK1/FGL1 axis in lung adenocarcinoma. Journal for ImmunoTherapy of Cancer, 12(10), e010077. https://doi.org/10.1136/jitc-2024-010077
Vancouver
Xu T, Fang Y, Gu Y, Xu D, Hu T, Yu T, et al. HDAC inhibitor SAHA enhances antitumor immunity via the HDAC1/JAK1/FGL1 axis in lung adenocarcinoma. Journal for ImmunoTherapy of Cancer. 2024;12(10):e010077. doi:10.1136/jitc-2024-010077
BibTeX
@article{Xu2024,
author = {Xu, Tingting and Fang, Yuan and Gu, Yunru and Xu, Duo and Hu, Tong and Yu, Tao and Xu, Yang-Yue and Shen, Hao-Yang and Ma, Pei and Shu, Yongqian},
title = {HDAC inhibitor SAHA enhances antitumor immunity via the HDAC1/JAK1/FGL1 axis in lung adenocarcinoma},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2024},
volume = {12},
number = {10},
pages = {e010077},
doi = {10.1136/jitc-2024-010077}
}
EUVIMED